20110706 Private Equity Summit Allen Lin
•
2 gostaram•1,658 visualizações
VC Investment in Biotech Industry
![Exploring the Business Opportunities in Taiwan- Perspectives on Biotech Investment Allen Lin ( 林群倫 ) YFY Biotech Management Company/ Taiwan Global Biofund July 6, 2011 4F, 51, Sec 2, Chung Ching South Rd. Taipei, Taiwan, R.O.C. Email: [email_address]](https://image.slidesharecdn.com/20110706pesummitallenlin-13100245451398-phpapp02-110707024747-phpapp02/85/20110706-Private-Equity-Summit-Allen-Lin-1-320.jpg)
![Outline ,[object Object],[object Object],[object Object],[object Object],[object Object]](data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7)
Recomendados
Mais conteúdo relacionado
Destaque
Destaque (19)
Último
Último (20)
20110706 Private Equity Summit Allen Lin
- 1. Exploring the Business Opportunities in Taiwan- Perspectives on Biotech Investment Allen Lin ( 林群倫 ) YFY Biotech Management Company/ Taiwan Global Biofund July 6, 2011 4F, 51, Sec 2, Chung Ching South Rd. Taipei, Taiwan, R.O.C. Email: [email_address]
- 5. Portfolio Companies Company name ： TaiMed Biologics http://www.taimedbiologics.com.tw/ Company name ： NeuroSky Inc. Website ： http://www.neurosky.com/ Company name ： CMS Website ： http://www.cmsholdings.com/ Company name ： Medigen Biology Cor. http://www.medigen.com.tw/
- 6. Private Equity Finance in Biotech Seed Fund ( Angel ) Corporate Partner ( VC ) Mezzanine round ( IB, Securities ) IPO 、 M&A 、 Licensing ( VC, PE, IB, HF )
- 7. Price is What You Pay, Value is What You Get – Warren Buffet
- 9. Deal flow by Industry, US Source ： PwC MoneyTree, Thomson Reuters (2009~2010)
- 10. US Biotech Financings ($M) Source ： Burrill&Company 2010 report
- 13. Biggest M&A in 2009 & 2010 $68 billion Wyeth (WYE) Pfizer (PFE) $18 billion Genzyme (GENZ) Sanofi-Aventis (SNY) $28 billion Alcon (ACL) Novartis (NVS) $47 billion Genentech (DNA) Roche (RHHBY.PK) $48 billion Schering-Plough (SGP) Merck (MRK) Deal Number Merged side Merging side
- 15. Biotech Market in Taiwan Unit: NT $100 M (Pharmaceuticals) (Emerging Biotecholgy) (Medical Devices) (Total) (Sectors) (Years) (Revenue) (Numbers of company) (Employee) (Export) (Import) (Import : Export) (Domestic Market)
- 16. Biotech Investment in Taiwan 資料來源：經濟部生物技術與醫藥工業發展推動小組， 2010 年生技白皮書。 Unit: NT $100 M Amount Pharmaceuticals Emerging Biotechology Medical Devices Total
- 19. Life Science Investment Thesis Source ： Burrill&Co. 2008 Report Building sustainable businesses K Biopharmaceuticals Seeds Food ingredients Bio Fuels Biomaterials Bio Processing Tools Agriculture Addressing major market needs Therapeutics Traits Diagnostics Wellness Enhancers Medical devices Services Human Health Care “ Sustain & Nourish the world” FEED THE WORLD FUEL THE WORLD HEAL THE WORLD
- 20. Historical Trends in Biotech Fields Source: National Center for Biotechnology Information, PubMed Proteomics RNAi Gene therapy
- 21. New Trends in Biogenerics Lonza Teva Imclone Eli Lilly MedImmune AstraZeneca Sandoz Novartis GlyFi+ IsMed+ Merck Bioventures Merck Strategy alliances or subsidiaries Company
- 22. Chinese Traditional Medicine in Taiwan Western Principle Or new system in Asia?
- 23. Success Rates and Time to Market across Therapeutic Areas Source: PharmaPredict.
- 24. Biotech Product Life Cycle
- 25. Source: LES royalty report on the pharmaceutical industry Licensing Strategy in Biotech
- 26. Biocluster in Taiwan Taiwan tops the World in the “State Of Cluster Development” For 3 consecutive years (WEF, 2006~2009) NanKang Biotech Park HsinChu Science Park HsinChu Biomedical Science Park Central Taiwan Science Park Southern Taiwan Science Park PingDong Agriculture Science Park Deep Ocean Biotech Park YiLan Biomedical Park
- 30. The Power of Social Networking in Medicine Source: PatientsLikeMe profile from Nature Biotech, Oct., 2009.
- 31. Hospital Mobile Phone Operators Cooperation Manufacturers of medical Device Promotion Business Model Wireless Body Network BD Phillips MicroLife Module sales Networking NTU hospital, Stanford Hospital &Clinics Strategy alliance & Clinical trial Chunghwa Telecom China Mobile
- 32. NeuroSky + Square Enix Uncle Milton Mattel
- 33. Cancer Progression Cancer Metastasis is responsible for the majority of mortality (>90% for Breast Cancer)
- 35. Blood vessel Primary tumor Circulating Tumor Cells in Blood Neutrophil: 50-70% Eosinophil: ~ 5% Basophil: ~ 1% Lymphocyte: 25-35% Monocypte: ~ 5% Red Blood Cells: ~ 1% In 1 mL of Blood: ~ 5 Million White Blood Cells ~ 5 Billion RBCs Veridex Test (7.5 mL):
- 36. PUMA: A New Substrate for Disposable Biochip
- 37. Size Based Cell Separation 7 m 2 m 7 m
- 41. Thank you for your attention!
Notas do Editor
- Our chips were developed with FDA regulatory requirement in mind: we pioneered a new chip substrate material, PUMA, which is a USP-Class VI medical grade material. This work was featured as the cover of Lab on a Chip in April of 2009.
- We have developed a system to reliably isolate CTCs from blood. Our system consists of a capital equipment and consumables: a chemical kit for tagging cancer cells, a disposable biochip that isolates CTCs from blood, and a microscopy system with eDAR technology for automating the sorting process and imaging the cells. In our recent clinical tests involving breast cancer patients we have recovered more than 100x cancer cells than a FDA-approved test.
- In Asia, there are five main countries, Singapore, Korea, China, Japan, and Taiwan developing their advantages in Biotech. Singapore build up the two Biotech Research Park, Tuas Biomedical Park and Biopolis, with tax-free policies and well facilities to attract GSK, Merck, Novartis, Pfizer to move into these regions. The big pharma provides the experts and talents and do the education for the local scientist. Korea’s biotech are highly-supporting from their government fund. Their government fund announce to give Samsung $3 Billion to develop the cancer new drug, and give LG Life Science $1.5 Billion to discover the stem cell therapeutics. In China, they don’t have a very advance technology, but they have advantage on the a big domestic market and low cost labor. In Japan, they have a very great basic and clinical research, and closed market for the foreign competitiors. In Taiwan, we have the best supply chain to do the OEM and ODM business in IT industry. In addition, we have more than 8,000 graduates in the bio-fields. However, the economic environment and well-constructed infrastructure are the key issues for Biotech Industry Success.